Search

CN-121971689-A - Gel dressing for relieving lymphedema after breast cancer operation and preparation method thereof

CN121971689ACN 121971689 ACN121971689 ACN 121971689ACN-121971689-A

Abstract

The invention belongs to the technical field of medical dressings, and in particular relates to a gel dressing for relieving lymphedema after breast cancer operation and a preparation method thereof, wherein the gel dressing comprises, by weight, 0.1-0.5 part of active drugs, 8-12 parts of modified matrixes, 0.2-0.8 part of dopamine hydrochloride, 2 parts of dispersing agents and 0.5-1.5 parts of reinforcing agents, wherein menthol with functions of promoting permeation, promoting diuresis and reducing edema is utilized to modify mussel mucin with good biocompatibility, so that the crosslinking and the gel forming performance of the mussel mucin are improved, and meanwhile, as a covalent bond is hydrolyzed and broken, the gel slowly collapses to release active drugs, and the active drugs are mutually cooperated with the menthol, so that the lymphedema after breast cancer operation is treated from various mechanism ways.

Inventors

  • LU MIMI
  • XU LILI
  • YU WEIWEI

Assignees

  • 平阳县人民医院

Dates

Publication Date
20260505
Application Date
20260311

Claims (6)

  1. 1. The gel dressing for relieving the lymphedema after breast cancer operation is characterized by comprising the following raw materials, by weight, 0.1-0.5 part of active medicine, 8-12 parts of modified matrix, 0.2-0.8 part of dopamine hydrochloride, 2 parts of dispersing agent and 0.5-1.5 parts of reinforcing agent; The modified matrix comprises mussel mucin, menthol, succinic anhydride, NHS, EDC and 2-iminothiolane, and the preparation method of the modified matrix comprises the following steps: S1, dissolving menthol, adding succinic anhydride into the menthol to react and steaming the menthol to obtain modified menthol; s2, jointly dissolving and reacting the modified menthol, NHS and EDC to obtain esterified menthol; s3, dissolving mussel mucin to obtain a protein solution, adding esterified menthol into the protein solution for reaction, and purifying to obtain modified protein; s4, adding 2-iminothiolane into the modified protein, and purifying and drying after the reaction is finished to obtain the modified matrix.
  2. 2. The gel dressing for alleviating lymphedema after breast cancer surgery according to claim 1, wherein the mass ratio of mussel mucin, menthol, NHS, EDC and 2-iminothiolane is 80:8:6:5:8:6.
  3. 3. A gel dressing for alleviating post-operative lymphedema of breast cancer according to claim 1, wherein said active agent is selected from any one of ketoprofen, doxycycline and VEGF-C.
  4. 4. A gel dressing for alleviating post-operative lymphedema of breast cancer according to claim 3, wherein said dispersing agent is selected from any one of β -cyclodextrin, tween 80 and BSA.
  5. 5. A gel dressing for alleviating post-operative lymphedema of breast cancer according to claim 3, wherein said enhancer is selected from any one of gelatin, nanocellulose and chitosan.
  6. 6. A method for preparing a gel dressing for alleviating lymphedema after breast cancer surgery according to any one of claims 1 to 5, comprising the following specific steps: Step 1, respectively dissolving an active medicine and a dispersing agent to obtain a liquid medicine and a dispersing liquid, dripping the liquid medicine into the dispersing liquid to obtain a pretreated liquid medicine, and dissolving a modified matrix and an reinforcing agent together to obtain a matrix liquid; Step 2, mixing the pretreatment liquid medicine and the matrix liquid to obtain a medicine carrying glue solution, dissolving dopamine hydrochloride, and then mixing the dissolved dopamine hydrochloride and the medicine carrying glue solution under the heating condition to obtain colloidal gel; and 3, placing the gelatinous gel in a mould, cooling, solidifying, forming and sterilizing to obtain the gel dressing for relieving lymphedema after breast cancer operation.

Description

Gel dressing for relieving lymphedema after breast cancer operation and preparation method thereof Technical Field The invention belongs to the technical field of medical dressings, and particularly relates to a gel dressing for relieving lymphedema after breast cancer operation and a preparation method thereof. Background The lymphedema after breast cancer operation is often related to factors such as armpit lymphatic reflux obstruction, radiotherapy fibrosis, local chronic inflammation and the like, clinically manifests as swelling, tightening, heaviness and dry skin itching in areas such as upper limbs or anterior axillary folds, inner sides of upper arms and the like, and is more prone to friction stimulation, maceration dermatitis and micro-cracks under the environment of long-term compression wearing of elastic sleeves/bandages. The risk of bacterial colonization or cellulitis increases after the skin barrier is compromised, and can cause swelling fluctuations or even exacerbations, forming a vicious circle of skin breakdown-infection/inflammation-edema. Therefore, the skin application product for lymphedema patients needs to have comfort, moisture permeability and biocompatibility, and also needs to have wet surface adhesion stability and control of local microenvironment. The existing hydrogel dressing mainly uses hyaluronic acid, alginate or single hydrophilic polymer as a matrix, mainly provides a moisturizing or simple drug carrying function, is insufficient in adhesion and retention under sweat and activity conditions, is easy to fall off and shift, is rapid and uncontrollable in drug release, is difficult to realize continuous, mild and controllable delivery under edematous skin environment, and has limited loading and percutaneous delivery efficiency of fat-soluble drugs, so that local effective drug flux is insufficient. Especially for the problems of tissue fluid retention, chronic inflammation, fragile skin barrier and the like related to lymphedema, the comprehensive treatment effect is difficult to realize. Disclosure of Invention Aiming at the situation, the invention provides the gel dressing for relieving the lymphedema after breast cancer operation and the preparation method thereof, and the gel dressing is based on modified biological materials to realize the gel property, so that the gel dressing has slow release, adhesion and enough mechanical strength, and the covalent bond breaks along with the deconstruction of a gel network to release active ingredients with the functions of promoting permeation and detumescence, and simultaneously improves the skin permeation efficiency of fat-soluble drugs, thereby achieving the purpose of lymphedema nursing and treatment. In order to achieve the above purpose, the technical scheme adopted by the invention is as follows: the invention provides a gel dressing for relieving lymphedema after breast cancer operation, which comprises the following raw materials, by weight, 0.1-0.5 part of active medicine, 8-12 parts of modified matrix, 0.2-0.8 part of dopamine hydrochloride, 2 parts of dispersing agent and 0.5-1.5 parts of reinforcing agent. Further, the active drug is selected from any one of ketoprofen, doxycycline and VEGF-C (vascular endothelial growth factor C). Further, the dispersant is selected from any one of beta-cyclodextrin, tween 80 and BSA (bovine serum albumin). Further, the reinforcing agent is selected from any one of gelatin, nanocellulose and chitosan. Further, the modified matrix comprises mussel mucin, menthol, succinic anhydride, NHS (N-hydroxysuccinimide), EDC (1-ethyl- (3-dimethylaminopropyl) carbodiimide) and 2-iminothiolane, wherein the mass ratio of mussel mucin, menthol, NHS, EDC and 2-iminothiolane is 80:8:6:5:8:6. Further, the preparation method of the modified substrate comprises the following steps: s1, dissolving menthol, adding succinic anhydride into the menthol, stirring the mixture for reaction, carrying out nucleophilic reaction on hydroxyl in the menthol and the succinic anhydride, opening the ring of the anhydride to form a half-ester structure, wherein one end of the anhydride is used for covalent connection with the menthol, the other end of the anhydride retains carboxyl, providing a reaction site for subsequent coupling with mussel mucin, and carrying out rotary evaporation after the reaction is finished to obtain modified menthol; S2, dissolving and reacting modified menthol, NHS and EDC together, wherein the EDC activates a carboxyl group reserved at one end of succinic anhydride in the modified menthol after ring opening to generate an O-acyl isourea intermediate, and NHS substitution is carried out to generate NHS active ester with more stability and higher reactivity to obtain esterified menthol; S3, dissolving mussel mucin to obtain a protein solution, adding esterified menthol into the protein solution while stirring for reaction covalent connection, carrying out affinity substitution on NHS ester